RxDoctor Payments Data

Danielle Trief, MD

Ophthalmology · New York, NYNPI 1154648087

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 20 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Alcon at 50.8% of the total. 2025 is the largest year on record at $824, more than ten times the $45 reported in 2019. That places this record below the midpoint for ophthalmology clinicians in NY, where the typical reported total is $1,047.

$1,244in general payments, 2019–2025

Across 20 payments — averaging $62.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$632
  • Dompe US, Inc.$276
  • Johnson & Johnson Surgical Vision, Inc.$138
  • Carl Zeiss Meditec, Inc.$108
  • Glaukos Corporation$68
  • Tarsus Pharmaceuticals, Inc.$22

What the payments were for

  • Food & beverage$1,244100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,244 in reported general payments places this provider in the 50th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York →

Medicare billing

Part B allowed, 2024
$385,397
Medicare patients
634
Services billed
2,428

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine49$41,213
XiidraLifitegrast31$24,776
Prednisolone Acetate312$13,370
Cyclosporine25$8,071
CombiganBrimonidine Tartrate/Timolol12$4,751
ProlensaBromfenac Sodium12$4,199
ValacyclovirValacyclovir Hcl55$2,681
Loteprednol Etabonate20$2,190
MoxifloxacinMoxifloxacin Hcl80$1,783
Bromfenac Sodium12$1,765
Timolol Maleate18$1,466
Difluprednate17$1,131
Ketorolac Tromethamine30$627
Latanoprost28$375
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha23$370

Paid to pharmacies, not to this prescriber.

Other ophthalmology in New York

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →